[{"id":"f1ad940d-0158-42e2-8647-51b32c5f7ee6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05565417","created_at":"2022-10-04T15:57:50.214Z","updated_at":"2024-07-02T16:35:06.273Z","phase":"Phase 1/2","brief_title":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05565417","lead_sponsor":"Immunitas Therapeutics","biomarkers":" KRAS • BRAF • ALK • PIK3CA • MET • MSI","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation","tags":["KRAS • BRAF • ALK • PIK3CA • MET • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • rezorstobart (IMT-009)"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 11/28/2022","start_date":" 11/28/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-03"}]